Response to Budget 2017
Research Australia welcomes first grants issued by Medical Research Future Fund
Government delivers on promise to establish flow of funding into health and medical research $20 billion capital target to be achieved in 2020-21
After a long-fought campaign to bring the Medical Research Future Fund (MRFF) to reality, health and medical researchers have welcomed the first round of grants issued from the MRFF, as announced tonight in the Federal Budget. $65.9 million is available for 2016/17, with the detail of $25 million of this spending released tonight. Just as importantly, we now have a clear path to achieving the capital target of $20 billion, with the Budget papers revealing this target will be achieved in 2020-21.
Research Australia Director and CSL’s Senior Vice President of Research, Dr Andrew Nash, said the Budget announcement tonight confirmed the Government has begun to deliver on its promise to establish a consistent flow of funding for health and medical research.
“The grants announced tonight represent an important milestone in the establishment of this landmark source of funding for health and medical research.
Continue reading “Federal Budget 2017-18 | First grants issued by MRFF”
We have just got out of the Health Portfolio Federal Budget Lockup and here’s some early news on items affecting our sector.
We will provide you with more details around how the Federal Budget 2017-18 directly impacts health and medical research in the next few hours.
- In 17-18, the total Health budget including (Aged Care & Sport) will increase 2.8% on last year to $94.2bn – that is 20% of total Commonwealth spend.
- $5bn of that relates to HMR which includes:
- $10M in preventive health research funded from MRFF
- $78.8m for cancer research including $68m for a Proton Beam Facility in South Australia and $14.8m for childhood cancer.
- Funding of $642.9 million will be made available in 2020 – 21, bringing total investment in HMR over the first 5 years of the MRFF to 1.4b, this is in addition to NHMRC funding.
- $374.2m for national expansion of My Health Record to an opt-out system as agreed by COAG last year which will deliver enormous savings to the nation’s health bill over the next decade.
- A compact with the pharmaceutical sector will mean lower cost medicines for consumers and in return allow more new drugs on the PBS and provide certainty and funding viability for the sector – congratulations to Medicines Australia
Continue reading “Federal Budget 2017-18 | Highlights”
This week, the Prime Minister announced that the Temporary Work (Skilled) visa (subclass 457 visa) will be abolished and replaced with the completely new Temporary Skill Shortage (TSS) visa in March 2018.
The TSS visa program will be comprised of a Short-Term stream of up to two years and a Medium-Term stream of up to four years and will support businesses ‘in addressing genuine skill shortages in their workforce and will contain a number of safeguards which prioritise Australian workers.’
Continue reading “Temporary Work (Skilled) visa subclass 457 scrapped”
Yesterday the Australian government launched the National Science Statement, outlining its commitment to science as part of the National Innovation and Science Agenda.
This comes in advance of the 2030 Strategic Plan for Innovation, Science and Research, with Innovation and Science Australia commissioned by the government to review Australia’s performance in science and innovation, and develop a plan through to 2030.
Research Australia welcomes the Statement’s long-term approach to science in Australia; in particular, the explicit references to secure and sustainable investment and recognition of the role of research as a central contributor to GDP. Continue reading “National Science Statement”
CRCs have played a key role in the translation of Australian health and medical research. Research Australia’s response to the Government’s consultation on Themes and Priorities for the CRC Programme took the opportunity to advocate for the reinstatement of Public Good CRCs, which are specifically excluded by the most recent Guidelines for the CRC Programme.
Research Australia’s Submission – CRC Themes Consultation
The Australian Government has consulted on changes to the personally controlled electronic health record (PCEHR) system, including moving to an opt out system, which creates the prospect of a much higher take up of the system and much greater utility to researchers in the future. While there is no proposed change to current arrangements in relation to research, the review offers the opportunity to influence how the system can be used for research purposes. Research Australia has supported the move to an opt out system, and has made a number of recommendations, including amending the legislation to allow identified data to be provided for data linking with other data sources for research purposes, and the indefinite retention of health records as a important resource for longitudinal research.
Electronic Health Records
In June 2013 the Australian Government issued a consultation paper seeking views on a proposal to assess the wider benefits of university based research. The paper proposed that a pilot exercise be undertaken in 2014 using case studies and quantitative data, and sought input on its design. Research Australia made a submission, urging a small scale ‘experimental’ approach using existing data to the greatest extent possible to test the feasibility and value of measuring research impact in this manner.
Assessing the wider benefits of university based research
In October 2012, the Australian Government announced a review of pharmaceutical patents, including the provisions for extending the terms of eligible pharmaceutical patents. The Review has issued a draft report with a number of interim findings and recommendations. Research Australia has made a submission to the Review, emphasising the important role that pharmaceutical patents play in encouraging innovation and competition, and the importance of providing a level of protection that is consistent with our collaborators in pharmaceutical development in the USA and Europe. Research Australia has also emphasised the important distinction between paying a drug company for its innovation by buying drugs under patent, and providing public funding for research.
Pharmaceutical Patents Review Draft Report